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Prenatal Diagnosis and Carrier Detection for a Point
Mutation in UBE3A Causing Angelman Syndrome
To the Editor:
Angelman syndrome (AS; MIM 105830) is a neuro-
behavioral disorder, characterized by severe mental re-
tardation, absence of speech, seizures, and gait ataxia
(Williams et al. 1995). AS is associated with maternal
deficiency of the E6-AP ubiquitin-protein ligase (UBE3A
gene; MIM 601623; Kishino et al. 1997; Matsuura et
al. 1997). Molecular analysis can distinguish five classes
of patients: those having a large deletion of a common
interval of ∼4 Mb on maternal chromosome 15q11-q13
(∼70% of cases), those having paternal uniparental di-
somy (UPD) (3%–5%), those having imprinting muta-
tions (7%–9%), those having intragenic mutations in
UBE3A (2%–4%), and those having a clinical diagnosis
of AS but with none of the above molecular abnormal-
ities (10%–20%). The first three classes of AS patients
demonstrate abnormal methylation patterns, by South-
ern blot analysis (Sutcliffe et al. 1994; Beuten et al. 1996)
or by PCR amplification of bisulphite-treated DNA (Ku-
bota et al. 1997), and are easily distinguished from the
AS patients who are candidates to have intragenic mu-
tations in UBE3A. Point mutations in UBE3A may be
de novo or may be present on the paternal chromosome
of mothers of affected children, which leads to a 50%
recurrence risk in subsequent pregnancies, in the latter
circumstance.
The UBE3A gene includes 10 exons that encode the
major open reading frame and additional upstream ex-
ons that are primarily noncoding but may contribute to
alternative isoforms (Yamamoto et al. 1997). Recent de-
lineation of the exon/intron organization (Yamamoto et
al. 1997) and the flanking intronic sequence of the major
coding exons of theUBE3A gene (Matsuura et al. 1997),
provide information for the design of PCR primers to
amplify the coding exons and splice boundaries (see
GenBank AF016703 to AF016708). We have used in-
tronic PCR primers (available from the authors upon
request; to be published elsewhere) to amplify and di-
rectly sequence genomic DNA, as described previously
(Matsuura et al. 1997).
A family of mixed Ashkenazi and Iraqi Jewish descent
with two children affected with AS was referred for
genetic counseling. The mother was pregnant and re-
quested prenatal diagnosis. Molecular analysis was per-
formed by use of DNA isolated from the two affected
children and their mother. Methylation analysis of the
family by use of Southern blot hybridization was nor-
mal, and ruled out common deletion, UPD, and imprint-
ing mutation as molecular abnormalities in this family
(data not shown). Sequence analysis for the 10 major
coding exons of UBE3A identified a nonsense muta-
tion in exon 15. The mutation was a GrA substitution
at nucleotide 2304 (numbering based on GenBank
X98032), which caused a nonsense mutation at tryp-
tophan codon 768 (W768X) at the protein level. Figure
1 illustrates the normal sequence from the father and
the heterozygous mutation in the patient, with direct
sequencing of amplified genomic DNA and the sequence
for the cloned mutation. The W768X mutation was pre-
sent in the mother of the affected children but was not
present in her two siblings (II-1 and II-2 in fig. 1).
Cytogenetic analysis of cultured aminocytes revealed
a normal female karyotype. Mutation analysis on DNA
from cultured aminocytes indicated that the fetus did
not inherit the W768X mutation from the mother. On
the basis of this information, the mother continued the
pregnancy and gave birth to a healthy female infant. The
absence of the W768X mutation was confirmed by test-
ing peripheral blood DNA from the infant, after birth.
In 70%–80% of cases of AS, the presence of the com-
mon ∼4-Mb deletion, paternal UPD, or imprinting mu-
tation, can be identified through the use of methylation
analysis, FISH, and DNA marker studies (American So-
ciety of Human Genetics/American College of Medical
Genetics Test and Technology Transfer Committee
1996). The recurrence risk is low for the common in-
terstitial deletion and for UPD but can be extremely high
in the case of chromosomal translocation or in some
imprinting mutations (Buiting et al. 1998). The remain-
ing 20%–30% of AS cases represent a difficult diag-
nostic problem, because mutation analysis for UBE3A
is only available on a limited basis, and because the
sequencing of all of the coding exons identifies a disease-
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Figure 1 Prenatal diagnosis and carrier detection. A, Pedigree:
half-blackened symbols (III-1 and III-2) indicate affected with AS and
heterozygous for the W768X mutation, half-hatched symbol (II-3)
indicates normal phenotype and heterozygous for the W768X muta-
tion, and divided nonblackened symbols (II-1, II-2, II-4, and III-3)
indicate normal phenotype and absence of the W768X mutation. B
and C, Direct sequencing of genomic DNA for the normal father and
for one of the affected children, respectively. D, DNA sequence for
the cloned mutation.
causing mutation in only ∼30% of the methylation-neg-
ative cases, in our experience. It is unknown whether
the remaining AS patients have other molecular abnor-
malities or represent potential misdiagnoses. When dis-
ease-causing mutations are identified, as in the family
reported here, the information is extremely valuable for
genetic counseling and prenatal diagnosis.
In patients with typical AS clinical findings and nor-
mal methylation studies, the family history should be
thoroughly investigated for the possibility of AS in dis-
tant maternal relatives, because the imprinted pattern of
inheritance may result in the occurrence of multiple af-
fected individuals, who are quite distantly related (Mei-
jers-Heijboer et al. 1992). Although mutation studies for
UBE3A would be valuable in all such families, they are
particularly indicated in families with more than one
individual affected with AS. In one report, mutations
were found in 80% of multiplex families and in 14%
of sporadic cases (Malzac et al. 1998), and we have
found mutations in 75% and 23% for these two groups,
respectively (P. Fang et al., unpublished data). In families
where we have found disease-causing mutations, the in-
dex case has represented a de novo mutation in about
half of the families, with the mother carrying the mu-
tation in the remaining group (P. Fang et al., unpublished
data). Thus, the risk of recurrence in families may be as
high as 50% or may be relatively low, and the two cir-
cumstances are easily distinguished if a mutation is iden-
tified. In instances where no mutation is identified but
where the clinical findings are typical of AS, considerable
uncertainty prevails. Recurrence of AS is uncommon in
this group but does occur.
To conclude, mutation analysis of UBE3A can be ex-
tremely informative for establishing a diagnosis of AS
and for genetic counseling. If a disease-causingmutation
is identified and is present in the mother, prenatal di-
agnosis is readily accomplished.
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